Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
This study has been completed.
First Posted: February 13, 2006
Last Update Posted: May 9, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Information provided by:
Pharmacology Research Institute
The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.
Major Depressive Disorder
||Primary Purpose: Treatment
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:
||18 Years to 65 Years (Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female patients 18-65 years of age, inclusive.
No Contacts or Locations Provided
History of Changes
|Other Study ID Numbers:
||February 9, 2006
||February 13, 2006
|Last Update Posted:
||May 9, 2012
Additional relevant MeSH terms:
Depressive Disorder, Major
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists